FLAURA
Osimertinib in Untreated EGFR-Mutated Advanced NSCLC
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 556 patients with untreated EGFR-mutated advanced NSCLC, osimertinib improved progression-free and overall survival compared with first-generation EGFR-TKI (gefitinib or erlotinib).
N
556
Disegno
Double-blind RCT
Esito
Progression-free survival
Rilevanza
2
RisultatoPFS 18.9 vs 10.2 months (HR 0.46). OS 38.6 vs 31.8 months (HR 0.80).
Soria JC, et al. N Engl J Med. 2018;378(2):113-125; Ramalingam SS, et al. N Engl J Med. 2020;382(1):41-50. 10.1056/NEJMoa1713137
Discussione e critica
Established osimertinib as first-line standard in EGFR-mutated NSCLC; superseded by FLAURA2 (osimertinib + chemo) in fit patients with high-risk features.